Background : Signal transducers and activators of transcription 3 (STAT3) and protein kinase substrate p36 may be involved in cell proliferation, differentiation and growth. Methods : Immunohistochemistry for STAT3 and p36 was performed in 46 patients with hepatocellular carcinoma (HCC). Results : STAT3 staining was present in the cytoplasm and/or nucleus, while p36 staining was present in the nucleus. STAT3 and p36 expression occurred in 78.3% (36/46) and 47.8% (22/46) of HCC patients, respectively. However, no correlation was found between STAT3 and p36 protein expression (p>0.05). Enhanced expression of STAT3 was negatively correlated with portal vein invasion (p=0.033). Expression of STAT3 in the nucleus was correlated with tumor grade (p=0.004). Enhanced expression of p36 was correlated with tumor grade (p=0.031). HCC was correlated with HBV infection (p=0.032). The patients' 5-year survival was related to expression of p36 (p=0.044), but not to total STAT3 or nuclear STAT3 (p>0.05). Conclusions : The enhanced expression of STAT3 in the nucleus and the enhanced expression of p36 are associated with the aggressive phenotype of HCC. Enhanced p36 expression may contribute to poor survival of patients with HCC.
Enhanced Protein Expression of Signal Transducer and Activator of Transcription 3 and Protein Kinase Substrate p36 in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, showing the highest prevalence in Asia and Africa.
1 It has a poor prognosis due to its rapid infiltrative growth and frequent association with liver cirrhosis as an underlying disease.
2 Recent advances in the understanding of molecular biomarkers involved in hepatocellular carcinogenesis have lead to novel and potential targeted therapeutic strategies.
3,4
However, our information about the usefulness of molecular markers associated with neoplastic proliferation in HCC is limited. Thus, we investigated two such markers, a signal transducer and activator of transcription 3 (STAT3) and protein kinase substrate p36, although no evidence has shown the relationship of these two markers.
STATs comprise a family of cytoplasmic transcription factors that transmit signals, usually generated by cell surface receptors, to the nucleus where STATs bind to specific DNA promoter sequences, thereby regulating gene expression. 5 STAT signaling is critical for normal cellular processes such as embryonic development, regulation of cell differentiation, growth, and apoptosis.
6 STAT3 was found frequently in a wide variety of human tumors, including hematologic malignancies such as leukemias, 7 solid head and neck tumors, 8 and hepatocellular carcinoma. p36 was first identified as a cellular protein kinase substrate phosphorylated by the Rous sarcoma virus-transforming gene product, pp60
v-src . 10 Subsequently, it was shown to be one of the most actively phosphorylated substrates for many of the retroviral gene products, as well as for the epidermal growth factor and platelet-derived growth factor receptor protein-kinases. Therefore, it is thought to be involved in the transformation process.
11,12
Evidence suggests that protein kinases, including protein kinase B (PKB)/Akt, extracellular signal related kinase (ERK), and mitogen activated protein kinase (MAPK) are involved in tumorigenesis of HCC. [13] [14] [15] Increased expression of p36 has been shown by western blot in human HCC. 16 We examined the expression of these protein molecular markers in HCC and compared them with clinicopathological parameters. Furthermore, the association of these markers with patient survival was evaluated. 
MATERIALS AND METHODS

Immunohistochemical staining
Immunohistochemical studies were performed using DAKO LSAB kits (DAKO A/S, Glostrup, Denmark). Tissue sections (4 μ m thick) were deparaffinized, rehydrated and incubated with 3% H 2O2 in methanol for 15 min at room temperature (RT) to eliminate endogenous peroxidase activity. The antigen was retrieved at 103 Kpa for 2 min by placing the slides in 0.01 M sodium citrate buffer (pH 6.0). The slides were then incubated with primary antibody STAT3 (1:100) or p36 (1:50) (Santa Cruz Biochemistry, Santa Cruz, CA, USA) at RT for one hour. After incubation at room temperature for 30 min with biotinylated secondary antibody, the slides were incubated with streptavidinperoxidase complex at room temperature for 30 min. Immunostaining was performed using chromogen and 3,3′ -diaminobenzidine (DAB), and counterstained with Mayer's hematoxylin. We used breast tissue (normal and cancer) as a positive control for STAT-3 and skin tissue (basal and suprabasal keratinocytes) as positive control for p36. The tissue sections processed without the primary antibody were used as the negative control.
Interpretation
The immunostaining of these markers was determined semiquantitatively according to the percentage of immunostained cells and staining intensity, as described previously.
17 A slide with ≤10% positive cells was scored as 0, 11-50% positive cells was scored as 1, 51-80% positive cells as 2, and >80% positive cells as 3. The intensity was scored as 1, 2, and 3 according to the low, moderate, and high intensity, respectively. The sum of these two scores was the final score. Immunoreactivity was graded as negative (less than 10% positive cells, regardless of intensity), low expression (1-3 score), or high expression (4-6 score; strongly positive). Immunohistochemical results were interpreted independently by two pathologists, and discussed with a third pathologist when their opinions differed.
Statistical analysis
Data were presented as absolute numbers and percentages. A 2 -test for nominal data was used to compare baseline characteristics. The Kaplan-Meier method was used to calculate 5-year survival curves and a log-rank test was used to compare the difference between the survival rates of patient subgroups. Reported p-values <0.05 were considered as significant.
RESULTS
Characteristics of STAT-3 and p36 expression in HCC
STAT-3 showed positive staining in 58.7%, 17.4%, and 23.9% of tumor cells in cytoplasm, nucleus and both, respectively ( Table  2 , Fig. 1B-D) . However, negative staining was found in the adjacent normal liver tissue (Fig. 1A) . Of the 46 patients, 10 (21.7%) had low expression and 36 (78.3%) has high expression. The intensity of p36 staining in the nucleus varied from weak to strong in tumor cells, and was negative in the adjacent normal liver tissue (Fig. 1E, F) . Of the 46 patients, 24 (52.2%) had low expression and 22 (47.8%) had high expression. There was no correlation in protein expression between STAT3 and p36 (p> 0.05).
Relationship between clinicopathological characteristics and the expression of STAT3 or p36 STAT3 protein expression correlated inversely with portal vein invasion (p=0.033). No correlation was found between the expression of STAT3 and tumor grade, tumor stage, tumor size, patient age or gender. However, the expression of STAT3 in the nucleus was significantly higher in grade 3-4 HCC than in grade 1-2 HCC (p=0.004, Table 2 ). p36 expression was significantly higher in undifferentiated and poorly differentiated HCC than in well and moderately differentiated HCC (p=0.031). Additionally, expression of p36 was positively associated with HBV infection (p=0.032). No correlation was found between expression of p36 and tumor stage, tumor size, patient age and gender (Table 1) .
Correlation of patients' survival and expression of STAT3 or p36
Thirty patients died (30/46, 65.2%) within 5 years after surgery.
The 1-, 3-, and 5-year survival rates were 43.3%, 20%, and 13.3 %, respectively. Kaplan-Meier survival curves and log-rank test showed a correlation between patients' 5-year survival and expression of p36 (p=0.044; Fig. 2C ), but not STAT3 (p=0.261, Fig.  2A ). The median survival times of low p36 expression and high p36 expression patients were 1,460 days and 730 days, respectively. In addition, STAT3 positivity in different localizations did not correlate with the 5-year survival of patients (p=0.946).
DISCUSSION
STAT3 is a recently discovered family of transcriptional factors responsible for regulating basic biological processes, such as cell proliferation, survival and differentiation.
5 Evidence suggests that STAT3 signaling is involved in promoting tumorigenesis as an oncogene. It is constitutively activated in many different tumor cell lines and primary tumors, including prostate, breast, ovary, and head and neck cancers. 8, [18] [19] [20] However, the clinicopathological significance of STAT3 in human HCC is unclear. Our study showed that no positive staining for STAT3 was found in adjacent normal liver tissues. However, high STAT3 expression occurred in both lower grade (79.3%) and higher grade (76.5%) HCC, indicating that the increase of STAT3 protein may contribute to the cellular transformation of normal cells into the malignant phenotype and that STAT3 may be a key factor that contributes to tumorigenesis. However, a negative association between STAT3 expression and portal vein invasion indicates that active STAT3 in nuclei may be involved in the progression of HCC. This is supported by our findings that STAT3 positivity in nuclei was higher in grade 3-4 than in grade 1-2 and by the significant association found between activation of STAT3 Follow-up interval (days) p36 lower expression p36 higher expression signaling pathway and the progression of ovarian cancer. 20 Our study showed STAT3 positivity in cytoplasm and/or nucleus, while Kannangai et al. 9 reported STAT3 nuclear positivity was present in 16% of HCC with no cytoplasmic positivity. These differences may be due to the different antibodies used. In addition, STAT3 in this study may include both inactive and active proteins, while STAT3 in another study may include just active proteins. Our finding of no correlation between patients' survival and either total STAT3 or nuclear STAT3 indicates a negative influence of STAT3 signaling on survival of patients with HCC. Pretreatment with dexamethasone reduced both the STAT3 activity and cell proliferation in a rat model of HCC. 21 Thus, it would be worthwhile to challenge tumors with more specific inhibitors of STAT3 to determine if they can reduce the growth of HCC.
Proliferation and cell growth marker p36 belongs to protein kinase substrates. p36 may be involved in Ca
2+
-mediated intracellular signal transduction. 22 One report demonstrated enhanced expression of p36 in human HCC, 16 suggesting that induction of p36 is associated with the poorly differentiated HCC expands the above finding. The induction of p36 results in rapid proliferation from normal hepatocytes to malignant phenotype and is involved in the actual malignant transformation process. More interestingly, p36 expression was significantly higher in HCC patients with HBV hepatitis than in HCC patients without hepatitis. This indicates that p36 may be an important mechanism of hepatocarcinogenesis common to HBV hepatitis. However, we cannot exclude the correlation between p36 expression and HCC with HCV hepatitis history because our materials had no HCV positive HCC cases. Recent studies suggest that Wnt/β -catenin pathway 23 and NF-κ B 24 are involved in HCC patients with hepatitis. The correlation between these events remains to be determined. More importantly, our finding that higher p36 expression was associated with poor survival in patients with HCC encourages us to consider that p36 signaling may be used in prognosis of HCC. However, this needs further investigation because 14/46 (38.8%) cases were censored in this study.
Although both STAT3 and p36 play important roles in cell proliferation, our results showed no correlation between STAT3 and p36 protein expression. This indicates that they may be involved in hepatocarcinogenesis through distinct signaling pathways.
In summary, the enhancement of expression of STAT3 or p36 is a frequent event in HCC. The enhanced expressions of STAT3 and of p36 in the nucleus are associated with aggressive phenotype of HCC. Enhanced p36 expression may contribute to poor survival of patients with HCC.
